Grant Will Award Up to $1 Million in Pulmonary Hypertension Research - The Cardiology Advisor

Grant Will Award Up to $1 Million in Pulmonary Hypertension Research - The Cardiology Advisor

Grant Will Award Up to $1 Million in Pulmonary Hypertension Research - The Cardiology Advisor

Posted: 31 May 2019 12:00 AM PDT

Pulmonary Hypertension Accelerated Bayer Awards, a new program launched by Bayer US, will award up to $1 million in grants to support clinical research in pulmonary hypertension, with a focus in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Grant applications will be open to physician practitioners and nonphysicians in the United States starting May 28 through June 30, 2019. Applicants will be expected to submit letters of intent with a short proposal that will be reviewed by an independent Grants Review Committee of 6 to 8 leading medical experts. After the initial evaluation, applicants will be invited to submit a full proposal by August 31, 2019.

The applications can be submitted within 4 categories of clinical research:

Level 1 is appropriate for investigators wishing to conduct a single center or restricted multicenter clinical trial in <5 sites in the United States. The award value is worth up to $200,000 total, the duration is for 2 years, and the maximum number of new awards per year is 2.

Level 2 is appropriate for early to midcareer professionals working pulmonary hypertension. The award value is worth up to $150,000 total, the duration is for 2 years, and the maximum number of new awards per year is 2.

Level 3 is appropriate for fellows and will be supporting research completed within the first 2 years of the applicant's first faculty position. The award value is worth up to $100,000 total, the duration of the award is for 2 years, and the maximum number of new awards per year is 2.

Level 4 is appropriate for allied health professionals working in pulmonary hypertension, including nurses, nurse practitioners, physiotherapists, pharmacists, and psychologists. The award value is worth up to $50,000 total, the duration of the award is for 1 to 2 years, and the maximum number of new awards per year is 2.

Related Articles

"The Pulmonary Hypertension Accelerated Bayer Awards is a reflection of our commitment to ensuring continued advancement in pulmonary hypertension science and care, and to the continued growth of young scientists, clinicians, and allied healthcare professionals involved in pulmonary hypertension research and education," said Aleksandra Vlajnic, MD, Vice President of Medical Affairs at Bayer in a press release.

The deadline for the letter of intent submissions is 12:00 AM PST, June 30, 2019. The entries will be evaluated on "significance, investigators, innovation, approach, and environment."

Reference

Bayer launches Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to help propel clinical advancements forward with up to 1 million dollars in grants [news release]. Whippany, NJ: Bayer; May 20, 2019.

This article originally appeared on Pulmonology Advisor

Topics:

Pulmonary Arterial Hypertension Pulmonary Hypertension

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Image
Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...
Read more

What to Expect During Pulmonary Embolism Recovery - Healthline

Image
What to Expect During Pulmonary Embolism Recovery - Healthline What to Expect During Pulmonary Embolism Recovery - Healthline Pulmonary Arterial Hypertension: Updates in Epidemiology and Evaluation of Patients - AJMC.com Managed Markets Network Right-Sided Heart Failure: Symptoms, Causes, and Treatments - Healthline Right sided heart failure: Symptoms, outlook, treatment - Medical News Today What to Expect During Pulmonary Embolism Recovery - Healthline Posted: 19 May 2021 12:00 AM PDT A pulmonary embolism (PE) is when a blood clot becomes stuck in the blood vessels of your lung. These clots typically begin in the leg and then break free and travel to the lung. The American Lung Association estimates that about 1 in 1,000 people in the United States experience a PE each year. A PE can be a serious or life threatening condition, which means receiving prompt medical treatment is vital. Treatment of a PE focus...
Read more